The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?
Open accessAbstract
Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show increased transmission fitness and/or immune evasion are classified as “variants of concern” (VOCs). Recently, a SARS-CoV-2 variant first identified in November 2021 in South Africa has been recognized as a fifth VOC, termed “Omicron.” What makes this VOC so alarming is the high number of changes, especially in the viral Spike protein, and accumulating evidence for increased transmission efficiency and escape from neutralizing antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Highly accurate protein structure prediction with AlphaFold
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Žídek, A., Potapenko, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03819-2 · Cited by 43,764
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · cited 1×
“ple, the increased infectiousness and reduced sensitivity to neutralization of the Delta VOC (13) with the lower susceptibility of the Alpha VOC to interferon-inducible innate immune”
BackgroundData, disease and diplomacy: GISAID's innovative contribution to global health
Elbe, S., & Buckland‐Merrett, G. (2017) · Global Challenges · doi:10.1002/gch2.1018 · Cited by 1,928 · cited 1×
“Sequences were obtained from GISAID and NCBI virus databases (96, 97) and aligned to Wuhan Hu-1 strain (NCBI: NC_045512.”
MethodStriking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Research works printed but not linked: 83
- 10.1038/s41577-020-00480-0 · DOI · Paper page
- 10.1038/d41586-021-03552-w · DOI · Paper page
- Grabowski F Kochańczyk M Lipniacki T. 2022. The spread of SARS-CoV-2 variant Omicron with the doubling time of 2.0–3.3 days can be explained by immune evasion. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.08.21267494v2. · DOI
- Bai Y Du Z Xu M Wang L Wu P Lau E Cowling BJ Meyers LA. 2021. International risk of SARS-CoV-2 Omicron variant importations originating in South Africa. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.07.21267410v1. · doi:10.1101/2021.12.07.21267410
- 10.2807/1560-7917.ES.2021.26.50.2101146 · DOI · Paper page
- 10.2807/1560-7917.ES.2021.26.50.2101147 · DOI · Paper page
- 10.1093/cid/ciab1041 · DOI · Paper page
- 10.1080/22221751.2021.2017757 · DOI · Paper page
- 10.1016/j.cell.2021.12.032 · DOI · Paper page
- 10.1038/s41586-021-04387-1 · doi:10.1038/s41586-021-04387-1 · Paper page
- Basile K Rockett RJ McPhie K Fennell M Johnson-Mackinnon J Agius JE Fong W Rahman H Ko D Donavan L Hueston L Lam C Arnott A Chen SC-A Maddocks S O’Sullivan MV Dwyer DE Sintchenko V Kok J. 2021. Improved neutralization of the SARS-CoV-2 Omicron variant after Pfizer-BioNTech BNT162b2 COVID-19 vaccine boosting. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472252v1. · DOI
- Cong Z Evans JP Qu P Faraone J Zheng Y-M Carlin C Bednash JS Zhou T Lozanski G Mallampalli R Saif LJ Oltz EM Mohler P Xu K Gumina RJ Liu S-L. 2021. Neutralization and stability of SARS-CoV-2 Omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.16.472934v1. · doi:10.1101/2021.12.16.472934v1
- Redd AD Nardin A Kared H Bloch EM Abel B Pekosz A Laeyendecker O Fehlings M Quinn TC Tobian AA. 2021. Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals. bioRxiv. 10.1101/2021.12.06.471446. · DOI
- Ahmed SF Quadeer AA McKay MR. 2021. SARS-CoV-2 T cell responses are expected to remain robust against Omicron. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472315v1. · DOI
- 10.1038/s41591-022-01700-x · DOI · Paper page
- Keeton R Tincho MB Ngomti A Baguma R Benede N Suzuki A Khan K Cele S Bernstein M Karim F Madzorera SV Moyo-Gwete T Mennen M Skelem S Adriaanse M Mutithu D Aremu O Stek C du Bruyn E Mescht MAVD de Beer Z de Villiers TR Bodenstein A van den Berg G Mendes A Strydom A Venter M Grifoni A Weiskopf D Sette A Wilkinson RJ Bekker L-G Gray G Ueckermann V Rossouw T Boswell MT Bihman J Moore PL Sigal A Ntusi NAB Burgers WA Riou C. 2021. SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.26.21268380v1. · doi:10.1101/2021.12.26.21268380
- Vihta K-D Pouwels KB Peto TE Pritchard E House T Studley R Rourke E Cook D Diamond I Crook D Matthews PC Stoesser N Eyre DW Walker AS Team C-19 IS. 2022. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. medRxiv. https://www.medrxiv.org/content/10.1101/2022.01.18.22269082v1. · doi:10.1101/2022.01.18.22269082
- Garrett N Tapley A Andriesen J Seocharan I Fisher LH Bunts L Espy N Wallis CL Randhawa AK Ketter N Yacovone M Goga A Bekker L-G Gray GE Corey L. 2022. High rate of asymptomatic carriage associated with variant strain Omicron. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.20.21268130v2. · DOI
- Christensen PA Olsen RJ Long SW Snehal R Davis JJ Saavedra MO Reppond K Shyer MN Cambric J Gadd R Thakur RM Batajoo A Mangham R Pena S Trinh T Kinskey JC Williams G Olson R Gollihar J Musser JM. 2022. Signals of significantly increased vaccine breakthrough decreased hospitalization rates and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston Texas. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.30.21268560v3. · doi:10.1101/2021.12.30.21268560
- Bentley EG Kirby A Sharma P Kipar A Mega DF Bramwell C Penrice-Randal R Prince T Brown JC Zhou J Screaton GR Barclay WS Owen A Hiscox JA Stewart JP. 2021. SARS-CoV-2 Omicron-B.1.1.529 variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.26.474085v2. · DOI
- Diamond M Halfmann P Maemura T Iwatsuki-Horimoto K Iida S Kiso M Scheaffer S Darling T Joshi A Loeber S Foster S Ying B Whitener B Floyd K Ujie M Nakajima N Ito M Wright R Uraki R Li R Sakai Y Liu Y Larson D Osorio J Hernandez-Ortiz J Čiuoderis K Florek K Patel M Bateman A Odle A Wong L-Y Wang Z Edara VV Chong Z Thackray L Ueki H Yamayoshi S Imai M Perlman S Webby R Seder R Suthar M Garcia-Sastre A Schotsaert M Suzuki T Boon A Kawaoka Y Douek D Moliva J Sullivan N Gagne M Ransier A Case J Jeevan T Franks J Fabrizio T DeBeauchamp J Kercher L Seiler P Singh G Warang P Gonzalez-Reiche AS Sordillo E van Bakel H Simon V. 2022. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq. https://www.researchsquare.com/article/rs-1211792/v1. · DOI
- McMahan K Giffin V Tostanoski LH Chung B Siamatu M Suthar MS Halfmann P Kawaoka Y Piedra-Mora C Martinot AJ Kar S Andersen H Lewis MG Barouch DH. 2022. Reduced pathogenicity of the SARS-CoV-2 Omicron variant in hamsters. bioRxiv. https://www.biorxiv.org/content/10.1101/2022.01.02.474743v1. · doi:10.1101/2022.01.02.474743
- 10.1016/j.virusres.2006.01.017 · DOI · Paper page
- 10.1111/febs.15815 · DOI
- 10.1371/journal.ppat.1000896 · DOI · Paper page
- 10.1016/j.molcel.2020.07.027 · DOI · Paper page
- 10.1186/s12977-015-0148-6 · DOI
- Bansal K Kumar S. 2021. Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.06.471389v1. · doi:10.1101/2021.12.06.471389
- Nchioua R Schundner A Klute S Noettger S Zech F Koepke L Graf A Krebs S Blum H Kmiec D Frick M Kirchhoff F Sparrer KMJ. 2021. The Delta variant of SARS-CoV-2 maintains high sensitivity to interferons in human lung cells. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.16.468777v1. · doi:10.1101/2021.11.16.468777
- Karim F Moosa MYS Gosnell BI Cele S Giandhari J Pillay S Tegally H Wilkinson E San JE Msomi N Mlisana K Khan K Bernstein M Manickchund N Singh L Ramphal U COMMIT-KZN Team Hanekom W Lessells RJ Sigal A de Oliveira T. 2021. Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infection. medRxiv. https://www.medrxiv.org/content/10.1101/2021.06.03.21258228v1. · DOI
- Wei C Shan K-J Wang W Zhang S Huan Q Qian W. 2021. Evidence for a mouse origin of the SARS-CoV-2 Omicron variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.14.472632v1. · doi:10.1101/2021.12.14.472632
- 10.1080/01652176.2021.1921311 · DOI · Paper page
- Stone S Rothan HA Natekar JP Kumari P Sharma S Pathak H Arora K Aurani TT Kumar M. 2021. SARS-CoV-2 variants of concern infect the respiratory tract and induce inflammatory response in wild-type laboratory mice. bioRxiv. https://biorxiv.org/cgi/content/short/2021.09.29.462373. · doi:10.1101/2021.09.29.462373
- 10.1016/j.ebiom.2021.103643 · DOI · Paper page
- 10.1016/j.tibs.2016.05.001 · DOI · Paper page
- 10.3390/v13030394 · DOI
- 10.1128/mSphere.00408-20 · DOI · Paper page
- 10.1016/j.bbrc.2020.10.092 · DOI
- 10.1038/s41598-018-24448-2 · DOI
- Chen X Kim K Calabrese P Wang S Qin C Rao Y Feng P. 2021. APOBEC-mediated editing of SARS-CoV-2 genomic RNA impacts viral replication and fitness. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.18.473309v1. · DOI
- Song Y He X Yang W Tang T Zhang R. 2021. ADAR mediated A-to-I RNA editing affects SARS-CoV-2 characteristics and fuels its evolution. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.07.22.453345v1. · DOI
- 10.1128/mBio.01930-20 · DOI · Paper page
- 10.1016/j.celrep.2021.109126 · DOI · Paper page
- 10.1128/mBio.02335-21 · DOI
- 10.1016/j.jinf.2020.03.058 · DOI · Paper page
- 10.1038/s41586-020-2368-8 · DOI · Paper page
- 10.1016/j.isci.2021.103353 · DOI
- Leary S Gaudieri S Parker MD Chopra A James I Pakala S Alves E John M Lindsey BB Keeley AJ Rowland-Jones SL Swanson MS Ostrov DA Bubenik JL Das S Sidney J Sette A COVID-19 Genomics UK (COG-UK) Consortium de Silva TI Phillips E Mallal S. 2021. Generation of a novel SARS-CoV-2 sub-genomic RNA due to the R203K/G204R variant in nucleocapsid: homologous recombination has potential to change SARS-CoV-2 at both protein and RNA level. bioRxiv. https://www.biorxiv.org/content/10.1101/2020.04.10.029454v4. · DOI
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- 10.1038/s41586-021-03925-1 · DOI · Paper page
- 10.1038/s41467-021-24817-y · DOI · Paper page
- 10.1038/s41392-021-00558-8 · DOI · Paper page
- Sarkar R Lo M Saha R Dutta S Chawla-Sarkar M. 2021. S glycoprotein diversity of the Omicron variant. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.04.21267284v2. · DOI
- Genovese L Zaccaria M Farzan M Johnson WE Momeni B. 2021. Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.01.470748v1. · doi:10.1101/2021.12.01.470748
- Zahradnik J Tuekprakhon A Ginn HM Duyvesteyn HME Bahar M Khan S Avinoam O Zhou D Nutalai R Supasa P Wang B Dejnirattisai W Liu C Dijokaite A Temperton N Mongkolsapaya J Fry EE Ren J Screaton GR Schreiber G Stuart DI. 2021. Receptor binding and escape from Beta antibody responses drive Omicron-B.1.1.529 evolution. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.03.471045v1. · DOI
- Golcuk M Yildiz A Gur M. 2021. The Omicron variant increases the interactions of SARS-CoV-2 Spike glycoprotein with ACE2. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.06.471377v1. · doi:10.1101/2021.12.06.471377
- Shah M Woo HG. 2021. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.04.471200v1. · doi:10.1101/2021.12.04.471200
- 10.1016/j.celrep.2021.109292 · DOI · Paper page
- 10.1038/s41467-020-20789-7 · DOI · Paper page
- 10.1016/j.chom.2020.06.020 · DOI · Paper page
- Escalera A Gonzalez-Reiche AS Aslam S Mena I Pearl RL Laporte M Fossati A Rathnasinghe R Alshammary H van de Guchte A Bouhaddou M Kehrer T Zuliani-Alvarez L Meekins DA Balaraman V McDowell C Richt JA Bajic G Sordillo EM Krogan N Simon V Albrecht RA van Bakel H Garcia-Sastre A Aydillo T. 2021. SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.09.467693v1. · DOI
- Peacock TP Brown JC Zhou J Thakur N Newman J Kugathasan R Sukhova K Kaforou M Bailey D Barclay WS. 2022. The SARS-CoV-2 variant Omicron shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.31.474653v1. · DOI · Paper page
- Liu Y Liu J Johnson BA Xia H Ku Z Schindewolf C Widen SG An Z Weaver SC Menachery VD Xie X Shi P-Y. 2021. Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. bioRxiv. 10.1101/2021.08.12.456173. · doi:10.1101/2021.08.12.456173
- Lista MJ Winstone H Wilson HD Dyer A Pickering S Galao RP Lorenzo GD Cowton VM Furnon W Suarez N Orton R Palmarini M Patel AH Snell L Nebbia G Swanson C Neil SJD. 2021. The P681H mutation in the Spike glycoprotein confers type I interferon resistance in the SARS-CoV-2 alpha (B.1.1.7) variant. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.09.467693v1. · DOI
- Wang Q Anang S Iketani S Guo Y Liu L Ho DD Sodroski JG. 2021. Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.27.474288v1. · DOI
- Zaccaria M Genovese L Farzan M Dawson W Nakajima T Johnson W Momeni B. 2021. Anticipating future SARS-CoV-2 variants of concern through ab initio quantum mechanical modeling. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.11.25.470044v1. · DOI
- Mannar D Saville JW Zhu X Srivastava SS Berezuk AM Tuttle K Marquez C Sekirov I Subramaniam S. 2021. SARS-CoV-2 Omicron variant: ACE2 binding cryo-EM structure of Spike protein-ACE2 complex and antibody evasion. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.19.473380v1. · DOI
- 10.1016/j.bbrc.2022.01.006 · DOI
- 10.1038/s41392-021-00863-2 · DOI · Paper page
- VanBlargan LA Errico JM Halfmann P Zost SJ Crowe JE Purcell LA Kawaoka Y Corti D Fremont DH Diamond M. 2021. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.15.472828v1. · DOI
- Cameroni E Saliba C Bowen JE Rosen LE Culap K Pinto D Marco AD Zepeda SK di Iulio J Zatta F Kaiser H Noack J Farhat N Czudnochowski N Havenar-Daughton C Sprouse KR Dillen JR Powell AE Chen A Maher C Yin L Sun D Soriaga L Gustafsson C Franko NM Logue J Iqbal NT Mazzitelli I Geffner J Grifantini R Chu H Gori A Riva A Giannini O Ceschi A Ferrari P Franzetti-Pellanda A Garzoni C Hebner C Purcell LA Piccoli L Pizzuto MS Walls AC Telenti A Virgin HW Lanzavecchia A Veesler D Snell G Corti D. 2021. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.12.472269v1. · doi:10.1038/d41586-021-03825-4 · Paper page
- Aggarwal A Stella AO Walker G Akerman A Milogiannakis V Brilot F Amatayakul-Chantler S Roth N Coppola G Schofield P Jackson J Henry JY Mazigi O Langley D Lu Y Forster C McAllery S Mathivanan V Fichter C Hoppe AC Munier ML Jack H-M Cromer D Darley D Matthews G Christ D Khoury D Davenport M Rawlinson W Kelleher AD Turville S. 2021. SARS-CoV-2 Omicron: evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern. medRxiv. https://www.medrxiv.org/content/10.1101/2021.12.14.21267772v1. · doi:10.1101/2021.12.14.21267772
- 10.1038/s41586-021-04005-0 · DOI · Paper page
- Vangeel L Chiu W Jonghe SD Maes P Slechten B Raymenants J André E Leyssen P Neyts J Jochmans D. 2022. Remdesivir molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.27.474275v2. · doi:10.1101/2021.12.27.474275
- Monteil V Stephanie D Klingström J Thålin C Kellner MJ Christ W Havervall S Mereiter S Knapp S Montserrat N Braunsfeld B Kozieradzki I Ali OH Hagelkruys A Stadlmann J Oostenbrink C Wirnsberger G Penninger JM Mirazimi A. 2021. Clinical grade ACE2 effectively inhibits SARS-CoV-2 Omicron infections. bioRxiv. https://www.biorxiv.org/content/10.1101/2021.12.25.474113v1. · DOI
- Bojkova D Widera M Ciesek S Wass MN Michaelis M Cinatl J. 2022. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates. bioRxiv. https://www.biorxiv.org/content/10.1101/2022.01.03.474773v1. · doi:10.1101/2022.01.03.474773
- 10.1080/22221751.2021.2023329 · DOI · Paper page
- Willett BJ Grove J MacLean OA Wilkie C Logan N Lorenzo GD Furnon W Scott S Manali M Szemiel A Ashraf S Vink E Harvey W Davis C Orton R Hughes J Holland P Silva V Pascall D Puxty K da Filipe AS Yebra G Shaaban S Holden MTG Pinto RM Gunson R Templeton K Murcia P Patel AH The COVID-19 DeplOyed VaccinE (DOVE) Cohort Study investigators The COVID-19 Genomics UK (COG-UK) Consortium The G2P-UK National Virology Consortium The Evaluation of Variants Affecting Deployed COVID-19 Vaccines (EVADE) investigators Haughney J Robertson DL Palmarini M Ray S Thomson EC. 2022. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change vaccine escape and a switch in cell entry mechanism. medRxiv. https://www.medrxiv.org/content/10.1101/2022.01.03.21268111v1. · DOI
- 10.1093/nar/gkw1065 · DOI · Paper page
- 10.1038/msb.2011.75 · DOI · Paper page
- 10.3390/v12091006 · DOI
- 10.1038/s41467-021-27180-0 · DOI
- 10.1038/s41586-020-2772-0 · DOI · Paper page
Cited by
Chatterjee, S., Bhattacharya, M., Nag, S., Dhama, K., & Chakraborty, C. (2023) · Viruses · doi:10.3390/v15010167 · Cited by 313
Oda, Y., Kumagai, Y., Kanai, M., Iwama, Y., Okura, I., Minamida, T., Yagi, Y., Kurosawa, T., Greener, B., Zhang, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00650-3 · Cited by 123
Nchioua, R., Diofano, F., Noettger, S., von Maltitz, P., Stenger, S., Zech, F., Münch, J., Sparrer, K. M. J., Just, S., & Kirchhoff, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01256-9 · Cited by 35
Self-citation
Metadata
- Authors
- Jung, C., Kmiec, D., Koepke, L., Zech, F., Jacob, T., Sparrer, K. M. J., & Kirchhoff, F.
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2022-03-23
- Volume
- 96
- Issue
- 6
- Pages
- e0207721-e0207721
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- OpenAlex
- W4214767539
- Cited by
- 213
- References
- 18
- FWCI
- 23.25
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- doi.org/10.1128/ASMCopyrightv2 (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Funders
- Bundesministerium für Bildung und Forschung (IMMUNOMOD, Restrict SARS-CoV-2)
- Deutsche Forschungsgemeinschaft (CRC 1279, SPP 1923, KM 5/1-1)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? https://app.cochat.ai/papers/10.1128/jvi.02077-21
- The paper
- Jung, C., Kmiec, D., Koepke, L., Zech, F., Jacob, T., Sparrer, K. M. J., & Kirchhoff, F. (2022). Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning? Journal of Virology. https://doi.org/10.1128/jvi.02077-21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.